Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY
Natália Polidorio , Srinivasa Sevilimedu Veeravalli , Giacomo Montagna , Tiana Le , Monica Morrow
Background: Clinicopathologic features of breast cancer subtypes defined by hormone receptor (HR) and HER2 status differ. These analyses classified HER2 IHC <3+ with negative FISH as HER2-. With the recognition of the clinical relevance of HER2 low, there is debate as to whether this is a distinct subtype. We sought to determine if features of HER2 low tumors differ from HER2- and HER2+ after controlling for HR status. Methods: Patients undergoing upfront surgery from 1998 to 2010 were identified from a prospectively maintained institutional database. HER2 status was classified by IHC/FISH analysis as HER2-, HER2 low (IHC 1+ or 2+ with negative FISH), and HER2+ (IHC 3+ or FISH +) and stratified by HR status. Univariable (UVA) and multivariable multinomial logistic regression analysis (MVA) were performed to determine associations among variables and subtypes. Results: 11,323 tumors from 11,072 patients were included. 5,104 (45%) were HER2 low, 41.2% were HER2- and 13.6% were HER2+. On MVA stratified by HER2 status only, compared to HER2- tumors, HER2 low was associated with LVI (OR 1.2 [95% CI 1.06-1.36]; p=.003), multifocality (OR 1.26 [95% CI, 1.12-1.42]; p<.001), nodal micrometastasis (OR 1.15 [95% CI, 1.02-1.31]; p=.024), and lower rates of <3 positive nodes (OR 0.77 [95% CI, 0.66-0.90], p=.001). HER2+ was associated with younger age, high grade, multifocality, extensive intraductal component (EIC), and pN2/3 nodal stage. Clinicopathologic features stratified by HR and HER2 status are shown in the table. On UVA, in both HR+ and HR– tumors, age and multifocality were associated with HER2 low, and LVI, multifocality, and EIC with HER2+ compared to HER2- tumors. On MVA, no variables were independently associated with both HR+ and HR-/HER2 low tumors compared to HER2-. In contrast, HER2+ tumors regardless of HR status were significantly associated with multifocality and EIC. Conclusions: HER2 low breast cancer features seem to be driven by HR status and HER2 overexpression. We do not have enough evidence to support the interpretation of HER2 low as a distinct subtype.
Characteristic n (%) | HR + | HR - | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
HER2- | HER2 low | p | HER2+ | p | HER2- | HER2 low | p | HER2+ | p | ||
3,807 | 4,596 | 1,007 | 862 | 508 | 543 | ||||||
Median age (IQR) | 58 (48, 68) | 57 (47, 66) | <0.01 | 51 (43, 61) | <0.01 | 53 (43, 63) | 55 (46, 65) | <0.01 | 53 (45, 61) | >0.9 | |
LVI | 968 (25) | 1,380 (30) | <0.01 | 440 (44) | <0.01 | 277 (32) | 173 (34) | 0.5 | 238 (44) | <0.01 | |
High grade | 1,666 (46) | 2,269 (51) | <0.01 | 815 (83) | <0.01 | 765 (93) | 451 (90) | 0.14 | 506 (94) | 0.2 | |
Multifocal | 961 (25) | 1,334 (29) | <0.01 | 327 (33) | <0.01 | 156 (18) | 120 (24) | 0.01 | 200 (37) | <0.01 | |
EIC | 347 (15) | 509 (16) | 0.2 | 171 (24) | <0.01 | 45 (8.5) | 50 (14) | <0.01 | 104 (30) | <0.01 | |
Nodal disease | |||||||||||
0 | 2,304 (61) | 2,814 (61) | 401 (40) | 463 (54) | 270 (53) | 251 (46) | |||||
Mic | 126 (3.3) | 221 (4.8) | <0.01 | 34 (3.4) | 0.02 | 15 (1.7) | 17 (3.4) | 0.06 | 17 (3.1) | 0.04 | |
1-2+ | 668 (18) | 773 (17) | 0.4 | 113 (11) | 0.8 | 130 (15) | 74 (15) | 0.9 | 105 (19) | <0.01 | |
≥ 3+ | 682 (18) | 778 (17) | 0.3 | 455 (45) | <0.01 | 250 (29) | 145 (29) | >0.9 | 168 (31) | 0.09 |
p values from multinomial UVA.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Seunghwan Shin
2022 ASCO Annual Meeting
First Author: Kaitlyn O'Keefe
2023 ASCO Annual Meeting
First Author: Victoria Chung
2023 ASCO Annual Meeting
First Author: Nawale Hajjaji